Edoxaban Is FDA Approved As Anticoagulant Therapy

Edoxaban Is FDA Approved As Anticoagulant Therapy

Edoxaban FDA Approved As Anticoagulant TherapyAs an effectual oral factor Xa inhibitor, Edoxaban is FDA approved as a novel anticoagulant therapy in the U.S. as an anticoagulant in several capacities:

  • To reduce the risk with of both systemic embolism and stroke in patients afflicted with atrial fibrillation (AF), which is not related to heart valve problems.
  • As a treatment for patients with pulmonary embolism and/or deep vein thrombosis (DVT) who have previously had at least 5-10 days of oral parenteral anticoagulant therapy.

While Edoxaban has been examined as a potential treatment for patients with mechanical heart valves and moderate-to-severe mitral stenosis this drug has not received an FDA approval for this use. Effective anti-clotting drugs, like Edoxaban, help to lower the risk of stroke in patients by helping to prevent blood clots from forming in the heart. The need for a wide variety of anticoagulant therapy is great, as many patients find current anti-clotting treatments elicit negative side effects, impacting their medication adherence. While there is a small risk for bleeding and anemia the majority of patients treated with Edoxaban fared well in studies.

Edoxaban, is also known as the brand name Savaysa, which is marketed by Daiichi Sankyo. Clinical trials of Edoxaban (Savaysa) were encouraging. One study involved 21,105 patients suffering from AF, which was not caused by cardiac valve disease. The higher dose of Edoxaban proved to be comparable to Warfarin for reducing stroke risk in patients, with significant decreases in major bleeding events as well. Another trial of patients afflicted with DVT and pulmonary embolism also supported the use of Edoxaban over Warfarin. This trial involved 8,292 participants and sought to reduce the rate of occurrence of symptomatic venous thromboembolism events, including mortality. Approximately 3.2 percent of patients administered Edoxaban experienced symptomatic venous thromboembolism events, as compared to 3.5 percent of the patients who received Warfarin.

LGM Pharma can assist clients as a supplier/distributor of the API Edoxaban CAS# 480449-70-5 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service